Dept of Respiratory Medicine, Hannover Medical School and Member of the German Center for Lung Research (DZL), Hannover, Germany.
The Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, USA.
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01906-2018. Print 2019 Jan.
Intensive care of patients with pulmonary hypertension (PH) and right-sided heart failure includes treatment of factors causing or contributing to heart failure, careful fluid management, and strategies to reduce ventricular afterload and improve cardiac function. Extracorporeal membrane oxygenation (ECMO) should be considered in distinct situations, especially in candidates for lung transplantation (bridge to transplant) or, occasionally, in patients with a reversible cause of right-sided heart failure (bridge to recovery). ECMO should not be used in patients with end-stage disease without a realistic chance for recovery or for transplantation. For patients with refractory disease, lung transplantation remains an important treatment option. Patients should be referred to a transplant centre when they remain in an intermediate- or high-risk category despite receiving optimised pulmonary arterial hypertension therapy. Meticulous peri-operative management including the intra-operative and post-operative use of ECMO effectively prevents graft failure. In experienced centres, the 1-year survival rates after lung transplantation for PH now exceed 90%.
肺动脉高压(PH)和右心衰竭患者的重症监护包括治疗导致或促成心力衰竭的因素、谨慎的液体管理以及降低心室后负荷和改善心功能的策略。体外膜氧合(ECMO)应在特定情况下考虑,特别是在肺移植候选人(移植桥)或偶尔在右心衰竭可逆原因患者(恢复桥)中。对于没有恢复或移植现实机会的终末期疾病患者,不应使用 ECMO。对于难治性疾病患者,肺移植仍然是一种重要的治疗选择。当患者尽管接受了优化的肺动脉高压治疗,但仍处于中危或高危类别时,应将其转介至移植中心。包括术中及术后使用 ECMO 的精细围手术期管理可有效预防移植物衰竭。在经验丰富的中心,PH 患者肺移植后的 1 年生存率现已超过 90%。